Get startedLog in
    Picture of Tanvex Biopharma logo

    6541 — Tanvex Biopharma Cashflow Statement

    0.000.00%
    tw flag iconLast trade - 00:00
    HealthcareSpeculativeSmall CapMomentum Trap
    Balance sheetIncome statementCashflow
    Subscribe to view all data

    Annual cashflow statement for Tanvex Biopharma, fiscal year end - December 31st, TWD millions except per share, conversion factor applied.

    2020
    December 31st
    2021
    December 31st
    2022
    December 31st
    2023
    December 31st
    2024
    December 31st
    Period Length:12 M12 M12 M12 M12 M
    Source:Annual Audited AccountsAnnual Audited AccountsAnnual Audited AccountsAnnual Audited AccountsAnnual Audited Accounts
    Standards:
    IFRS
    IFRS
    IFRS
    IFRS
    IFRS
    Status:FinalFinalFinalFinalFinal
    Net Income/Starting Line-2,104-1,543-1,641-2,137-1,381
    Depreciation
    Amortisation
    Non-Cash Items80.56.3512036739.5
    Unusual Items
    Other Non-Cash Items
    Changes in Working Capital15.6-93.8-94.210.8-97.9
    Change in Accounts Receivable
    Change in Inventories
    Change in Prepaid Expenses
    Change in Accounts Payable
    Change in Accrued Expenses
    Change in Other Liabilities
    Other Operating Cash Flow
    Cash from Operating Activities-1,788-1,387-1,334-1,434-1,151
    Capital Expenditures-67.5-30.3-96.1-71.3-111
    Purchase of Fixed Assets
    Purchase / Acquisition of Intangibles
    Other Investing Cash Flow Items-1765.66-1.27-12.21.51
    Sale of Fixed Assets
    Sale/Maturity of Investment
    Purchase of Investments
    Other Investing Cash Flow
    Cash from Investing Activities-243-24.7-97.4-83.6-109
    Net Issuance / Retirement of Stock
    Net Issuance / Retirement of Debt
    Cash from Financing Activities1,7301,597-1231,0801,255
    Foreign Exchange Effects
    Beginning Cash Balance
    Ending Cash Balance
    Net Change in Cash-359154-1,437-405-3.79